Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

University of Calgary

Headquarters: Calgary, AB, Canada
Year Founded: 1966
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

An analysis of BioCentury’s Distillery captures trends from preclinical publications in 2020
BioCentury | Oct 28, 2020
Distillery Therapeutics

Inhibiting IL-33-driven inflammation to treat brain cancer

DISEASE CATEGORY: Cancer
INDICATION: Brain cancer Targeting nuclear accumulation of IL-33 could treat glioblastoma multiforme by reducing recruitment of pro-tumorigenic innate immune cells to the
BioCentury | Jun 26, 2020
Distillery Therapeutics

FMR1 peptide therapy for Fragile X syndrome

BioCentury | Jun 20, 2019
Distillery Therapeutics

MHCII nanoparticles for autoimmune hepatic diseases

BioCentury | May 17, 2019
Company News

Management tracks: AstraZeneca, Certara, Longas

BioCentury | Oct 18, 2018
Distillery Therapeutics

Inflammation

BioCentury | Aug 16, 2018
Distillery Therapeutics

Neurology

BioCentury | Jul 19, 2018
Translation in Brief

Inflammatory images

How inflammasome activation mediates contrast agent-induced acute kidney injury
BioCentury | Mar 13, 2018
Distillery Therapeutics

Infectious disease

Items per page:
1 - 10 of 57